CareDx CEO says company preparing for more competition

CareDx (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of diagnostic solutions for transplant recipients, joined The Fly for an exclusive interview. In the interview, CareDx CEO Peter Maag discussed competition and the company’s lawsuit against Natera (NTRA): “Natera is trying to cut corners in bringing their solution to the market. We have worked for 7/8 years to build and make this technology available to transplant patients. And now, I think they’re trying to adopt a fast follower strategy. I think it’s very important to realize that CareDx has relevant IP in the state and that we have established relationships with transplant centers. We’re making sure that we are linking ourselves with these 250 transplant centers in the country, being part of their workflow and caring for patients versus being a company that says, ‘oh I have one more test and I can do that as well.’ This is very critical as we are preparing for more competition in a market, in heart transplant, where we used to be the only company and now there might be other companies coming in the future. So, we are embracing competition.” “Meet the Company” is The Fly’s recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. https://thefly.com/landingPageNews.php?id=2886949